why choose us

First received: October 06, 2023

Clinical Trial: A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

Brief Summary: The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma.In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

Read more